文献速递脑血管病

脑出血后短期与长期医疗资源利用及费用

Short- and Long-term Health Care Resource Utilization and Costs Following Intracerebral Hemorrhage.
PubMed 文献 · Neurology · 2021-06-09

该研究基于加拿大安大略省全人群2009-2017年成人脑出血患者数据,评估1年直接医疗费用及口服抗凝药(OAC)与费用的关联。共纳入16,248例患者,1年死亡率为46.0%,中位1年总费用为26,886美元,存活出院者费用显著高于院内死亡者;OAC使用与1年总费用升高独立相关。

要点

  • 脑出血后1年中位总费用为26,886美元,存活出院者费用远高于院内死亡者。
  • 口服抗凝药使用与1年总费用升高独立相关(费用比1.06)。
  • 未来治疗应致力于减少残疾而非仅降低死亡率以提升成本效果。

核心结论

  • 脑出血与显著医疗费用相关,患者中位费用约为安大略省中位住院费用的10倍。
  • 存活患者费用高于死亡患者,口服抗凝药使用独立关联费用增加。

研究设计与样本

  • 回顾性队列研究,纳入加拿大安大略省全人群2009-2017年成人(≥18岁)脑出血患者,通过健康行政数据库链接获取结局。
  • 采用广义线性模型识别与总费用相关的因素,口服抗凝药分析限于≥66岁患者。

主要发现

  • 共16,248例脑出血患者,平均年龄71.2岁,男性占52.3%,1年死亡率为46.0%,24.2%需机械通气。
  • 中位1年总费用为26,886美元(IQR 9,641-62,907),院内死亡者费用为7,268美元(IQR 4,031-14,966),存活出院者为44,969美元(IQR 20,264-82,414,p<0.001)。
  • 口服抗凝药使用(≥66岁患者)与更高的1年总费用相关(费用比1.06,95%CI 1.01-1.11)。
  • 整个队列1年总费用在研究期间每年超过1.2亿美元。

临床怎么用

  • 临床应关注脑出血后长期康复与残疾管理,以降低总体医疗费用。
  • 对使用口服抗凝药的患者,需权衡费用与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to evaluate the short- and long-term resource use and costs associated with intracerebral hemorrhage (ICH) taken from an entire population. We in addition sought to evaluate the association of oral anticoagulation (OAC) and health care costs. METHODS: This was a retrospective cohort study of adult patients (≥18 years) with ICH in the entire population of Ontario, Canada (2009-2017). We captured outcomes through linkage to health administrative databases. We used generalized linear models to identify factors associated with total cost. Analysis of OAC use was limited to patients ≥66 years of age. The primary outcome was total 1-year direct health care costs in 2020 US dollars. RESULTS: Among 16,248 individuals with ICH (mean age 71.2 years, male 52.3%), 1-year mortality was 46.0%, and 24.2% required mechanical ventilation. The median total 1-year cost was $26,886 (interquartile range [IQR] $9,641-$62,907) with costs for those who died in hospital of $7,268 (IQR $4,031-$14,966) vs $44,969 (IQR $20,264-$82,414, p < 0.001) for survivors to discharge. OAC use (analysis limited to individuals ≥66 years old) was associated with higher total 1-year costs (cost ratio 1.06 [95% confidence interval 1.01-1.11]). Total 1-year costs for the entire cohort exceeded $120 million per year over the study period. CONCLUSIONS: ICH is associated with significant health care costs, and the median cost of a patient with ICH is roughly 10 times the median inpatient cost in Ontario. Costs were higher among survivors than deceased patients. OAC use is independently associated with increased costs. To maximize cost-effectiveness, future therapies for ICH must aim to reduce disability, not only improve mortality.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fernando SM, Qureshi D, Talarico R, et al. Short- and Long-term Health Care Resource Utilization and Costs Following Intracerebral Hemorrhage. Neurology. 2021. PMID: 34108269. doi:10.1212/WNL.0000000000012355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。